- Home
- OBE vs CGEM Comparison
OBE vs CGEM Comparison
Compare OBE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- CGEM
- Stock Information
- Founded
- OBE 1979
- CGEM 2016
- Country
- OBE Canada
- CGEM United States
- Employees
- OBE N/A
- CGEM N/A
- Industry
- OBE Oil & Gas Production
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- CGEM Health Care
- Exchange
- OBE Nasdaq
- CGEM Nasdaq
- Market Cap
- OBE N/A
- CGEM 506.1M
- IPO Year
- OBE N/A
- CGEM 2021
- Fundamental
- Price
- OBE $5.87
- CGEM $8.02
- Analyst Decision
- OBE Strong Buy
- CGEM Strong Buy
- Analyst Count
- OBE 1
- CGEM 8
- Target Price
- OBE $14.00
- CGEM $32.86
- AVG Volume (30 Days)
- OBE 444.8K
- CGEM 411.9K
- Earning Date
- OBE 05-01-2025
- CGEM 05-14-2025
- Dividend Yield
- OBE N/A
- CGEM N/A
- EPS Growth
- OBE N/A
- CGEM N/A
- EPS
- OBE N/A
- CGEM N/A
- Revenue
- OBE $508,187,151.00
- CGEM N/A
- Revenue This Year
- OBE $11.82
- CGEM N/A
- Revenue Next Year
- OBE $24.27
- CGEM $278.37
- P/E Ratio
- OBE N/A
- CGEM N/A
- Revenue Growth
- OBE 11.92
- CGEM N/A
- 52 Week Low
- OBE $4.74
- CGEM $7.90
- 52 Week High
- OBE $9.07
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- OBE 58.89
- CGEM 36.91
- Support Level
- OBE $5.83
- CGEM $8.01
- Resistance Level
- OBE $6.22
- CGEM $9.16
- Average True Range (ATR)
- OBE 0.23
- CGEM 0.48
- MACD
- OBE 0.07
- CGEM -0.00
- Stochastic Oscillator
- OBE 71.77
- CGEM 4.90
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.